is a development-stage
pharmaceutical company based in San Diego, California, working to
become the world leader in the development of a new class of
investigational drugs known as immune regulating hormones (IRHs). Hollis-Eden is also developing IRHs for protection from
chemotherapy and other conditions of immune dysregulation such as
autoimmunity . The
actual results may differ materially from those contained in this
press release.
Hollis -Eden Pharmaceuticals, Inc. Ed
Mitchell, Vice President of Product Development.

findarticles circumcision

HIV, Malaria + TB, " is sponsored
by BIO Ventures for Global Health.
eastern standard time on Thursday, February 24 , 2005. Cogburn previously worked in discovery,
preclinical and clinical research with G.D.
She received a Ph.D.

crain findarticles

Hollis-Eden Pharmaceuticals CEO to Participate in Global Disease Funding Panel and Deliver Corporate Presentation at BIO CEO + Investor Conference 2005

Burgess, Chief Financial Officer and COO, will deliver a corporate
presentation at the SG Cowen + Co.m. The Company has a number of
investigational compounds under development, including NEUMUNE(TM),
which the Company is developing for use in protection from Acute
Radiation Syndrome (ARS); PHOSPHONOL(TM), a non-IRH candidate for
providing protection against DNA mutations from radiation exposure and
chemotherapy treatment; and IMMUNITIN(TM), which has shown activity in
a variety of infectious diseases, including HIV/AIDS , tuberculosis and
malaria. Hollis-Eden is also developing IRHs for protection from
chemotherapy and other conditions of immune dysregulation such as
autoimmunity. Any statement describing a goal , expectation,
intention or belief of the Company is a forward-looking statement and
should be considered an at-risk statement. Prather will manage development of Axifa(TM),
an anti-inflammatory and mucolytic compound designated initially for cystic
fibrosis. in Botany
from the University of Iowa.

ramex findarticles

. She also has served as an independent regulatory
consultant and has practiced law in private practice.

crain scicentral

The
goal of IRH therapy is to direct, through controlling gene expression,
the production of key cytokines and enzymes that re-regulate immune
and metabolic functions toward homeostasis, a profile that could be
useful in a wide variety of diseases.

crain mdtv

The Company has a number of
investigational compounds under development, including NEUMUNE(TM),
which the Company is developing for use in protection from Acute
Radiation Syndrome (ARS); PHOSPHONOL(TM), a non-IRH candidate for
providing protection against DNA mutations from radiation exposure and
chemotherapy treatment; and IMMUNITIN(TM), which has shown activity in
a variety of infectious diseases, including HIV/AIDS, tuberculosis and
malaria . 25th Annual Healthcare Conference
in Boston at 10:30 a.
The webcast will be archived at the Company 's website for 30 days
following the presentation.
"We are very pleased that Nita Cogburn and Susan Prather have joined
airPharma to propel the development of these two promising products.

indepth allafrica

Mr . Dr. The company was
founded in 2002 by Dr.

All sites providing information pertaining to news and current events related to Health.

tb biologics

com

This press release contains forward-looking statements concerning
the potential and prospects of the Company's drug discovery program
and its drug candidates. A live webcast of the presentation will be available from the
conference. Such statements are subject
to certain risks and uncertainties, including the ability to
successfully complete preclinical and clinical trials within specified
timelines, if at all; the ability to obtain regulatory approval for
NEUMUNE, even if shown to be effective in preclinical studies; the
ability to receive any stockpiling orders for NEUMUNE from the U. in Biology from Brandeis University and a B.

indepth findarticles

Hollis-Eden Pharmaceuticals, Inc. For more information on Hollis-Eden, contact the
Company's website at www. Cogburn brings 18 years of experience in developing and leading
programs in pharmaceutical development, from early discovery research to
clinical research. Ms.

scicentral cystic

J.
She joins airPharma from Sanofi-Aventis, where she led global project teams
responsible for regulatory strategy for changes in the manufacturing of
strategic products. Prather provided regulatory interaction, support and oversight of
submission strategies. Prather received a
J.D.com .

circumcision cystic

Hollis also will be a corporate presenter at 12:00 p. For more information on Hollis-Eden, contact the
Company's website at www.
airPharma will begin Phase I/II clinical trials for Zofac(TM) and
Axifa(TM) later this year.S .air-pharma.

fibrosis cystic

, airPharma, a specialty
pharmaceutical company focusing on products to address unmet needs in
respiratory diseases, today announced the appointment of two experienced
managers as Directors of Product Development to guide the clinical and
regulatory progress of the company's two lead products.A. airPharma is privately held and is
located in Overland Park, KS.

bna approvals

Investors may access the webcast under "Event Calendar" on the
Investors section of Hollis-Eden's website at www .

Hollis-Eden Pharmaceuticals to Present at SG Cowen + Co. 25th Annual Healthcare Conference

25th Annual Healthcare Conference

SAN DIEGO----Hollis-Eden
Pharmaceuticals, Inc. The
goal of IRH therapy is to direct, through controlling gene expression,
the production of key cytokines and enzymes that re-regulate immune
and metabolic functions toward homeostasis, a profile that could be
useful in a wide variety of diseases.com

This press release contains forward-looking statements concerning
the potential and prospects of the Company's drug discovery program
and its drug candidates .

headlinespot headline

Business Editors/Biotech Writers/Tradeshow Writers
SG Cowen + Co. in Biology from UMKC.

intelihealth newsfeed

holliseden.holliseden.holliseden. As we
commercialize important new therapies for diseases of the airways, airPharma
is building an effective team of experienced pharmaceutical people," said Doug
Dockhorn, President and Chief Executive Officer. She was a postdoctoral fellow at Harvard Medical
School and the Veterans Administration.

allafrica datamonitor

(NASDAQ:HEPH) today announced that Richard B..com.com., a specialty
pharmaceutical company focusing on products based on proprietary drug delivery
technologies , where she led product development teams for 505(b)(2)
submissions to the FDA. degree from the School of Law at the University of Missouri-Kansas City
and a B.

circumcision newsweekly

The company is
developing a portfolio of branded respiratory products.

allafrica headline

These contracts could be
similar to those being awarded to industry by the U.

airPharma Names Directors of Product Development

crain reuters

The
webcast will be archived at the Company's website for 30 days
following the presentation. Any statement describing a goal, expectation ,
intention or belief of the Company is a forward-looking statement and
should be considered an at-risk statement. Such statements are subject
to certain risks and uncertainties, including the ability to
successfully complete preclinical and clinical trials within specified
timelines, if at all; the ability to obtain regulatory approval for
NEUMUNE, even if shown to be effective in preclinical studies; the
ability to receive any stockpiling orders for NEUMUNE from the U. The two directors will coordinate the company's
internal team and scientific partners, as well as liaisons with the Food and
Drug Administration (FDA), to design and execute clinical trials and prepare
regulatory submissions. Searle, Monsanto and Pharmacia. Previously, as Marion Merrell Dow's principal project
liaison with the FDA for Oncology and Anti-Infective/Anti-Viral drug products,
Ms. Prior to airPharma ,
the Dockhorns built their previous company, IMTCI, into the leader in
conducting respiratory clinical studies. For further information, visit airPharma's
website at http://www.

biologics circumcision

m. A live webcast
of the corporate presentation will be available from the conference.S. (NASDAQ:HEPH) today announced that Daniel D. The
actual results may differ materially from those contained in this
press release . Experienced Managers Will Guide Two Lead Products of airPharma

OVERLAND PARK, Kan .

newsweekly crain

government
under Project BioShield for medical countermeasures against weapons of
mass destruction . Investors may access the webcast under "Event Calendar" on
the Investors section of Hollis-Eden 's website at www. is a development-stage
pharmaceutical company based in San Diego, California, working to
become the world leader in the development of a new class of
investigational drugs known as immune regulating hormones (IRHs).S.
and foreign governments, even if approved by regulatory authorities;
the Company's future capital needs; the Company's ability to obtain
additional funding; the ability of the Company to protect its
intellectual property rights and to not infringe the intellectual
property rights of others; the development of competitive products by
other companies; and other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission. Nita Cogburn will
oversee Zofac(TM), a dry-powder surfactant under development for the treatment
of allergic asthma, and Susan J.

About airPharma
airPharma is a specialty pharmaceutical company focused on commercializing
products that address unmet needs in respiratory diseases.

intelihealth mdtv

Pharmaceutical Writers/Business Editors/Economics + Financial
Writers
BIO CEO + Investor Conference 2005

SAN DIEGO----Hollis-Eden
Pharmaceuticals, Inc.
Hollis, Chairman and CEO, will discuss innovative public/private
partnership funding strategies for global infectious diseases on a
Business Roundtable at the BIO CEO + Investor Conference in New York
City on February 23, 2005. Potential funding strategies include "pull"
mechanisms, such as advance purchase contracts that guarantee markets
and incentivize industry to invest in the development of new vaccines
and therapies for global infectious diseases .

holliseden.
Ms. Robert Dockhorn and Doug Dockhorn.

intelihealth crain

and foreign governments, even if approved by regulatory authorities;
the Company's future capital needs; the Company's ability to obtain
additional funding; the ability of the Company to protect its
intellectual property rights and to not infringe the intellectual
property rights of others; the development of competitive products by
other companies; and other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission. Prather has broad experience in global project management , regulatory
and development strategies, and Chemistry, Manufacturing and Controls (CMC).

biologics tuberculosis

S. The Business Roundtable, "Strategies for Creating a
Real Market for Neglected Diseases. She joins airPharma from CyDex, Inc.

looksmart ramex

eastern standard time on Wednesday, March 16,
2005. "Nita and Susan have in-depth experience in project
team leadership, product development and regulatory relationships, which will
add great value as we move forward with these two products," said Dr.
Dr.